Tuesday, May 23, 2023
Coherus BioSciences announced that the single-dose (6mg/0.6mL), prefilled autoinjector presentation of UDENYCA® (pegfilgrastim-cbqv) is now available for commercial sale in the United States.
UDENYCA® is a pegfilgrastim biosimilar administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia. UDENYCA® AI’s streamlined design offers a simple option for in-office and at-home settings of care that administers pegfilgrastim in less than 10 seconds.
UDENYCA® AI has user-friendly features that promote successful delivery. UDENYCA® is the only pegfilgrastim product offering two on-demand options—prefilled syringe and autoinjector, with a third, proprietary on-body injector (OBI) under review by the FDA. With UDENYCA AI, providers now have a new option that offers the patients where and how to receive their therapy, and health plans have a new option to increase access for patients.
UDENYCA® AI fulfils high unmet need by giving providers a new, innovative option that offers patients greater choice, independence and flexibility. If approved, the UDENYCA® OBI will offer providers a highly desired alternative to the originator’s on-body pegfilgrastim delivery system.